By Dr Bianca Crook, South African general
practitioner
Medically reviewed: 1 September 2026
The “best” GLP-1 dose is not the highest dose and it is not the dose another person uses. It is the dose and treatment plan that are appropriate for the specific medicine, indication, response, tolerability and clinical circumstances. Dose escalation is a safety and treatment decision, not a competition.
Key points
- Starting doses are commonly used to help the body adjust.
- Escalation schedules differ between products and indications.
- More side effects do not prove that a medicine is working better.
- Do not accelerate, double or improvise doses.
- A plateau does not automatically mean the dose should increase.
Why treatment often starts low
GLP-1 and GIP/GLP-1 medicines affect appetite and digestion, and some slow gastric emptying. Nausea, vomiting, diarrhoea, constipation and abdominal discomfort are common adverse effects. Approved schedules commonly begin with a lower dose and increase in stages to reduce gastrointestinal intolerance.
That lower first dose may be described in the product information as an initiation dose rather than a maintenance dose. This does not make it “too weak” or a failed treatment. Its job is partly to introduce the medicine safely.
The exact schedule is not interchangeable across semaglutide, tirzepatide or other products. It can also differ according to the approved indication. A Mounjaro patient-education discussion, for example, should use the approved information for that product and country, not a schedule copied from a Wegovy patient-education post.
What should guide a dose review
A clinician may consider several questions before changing a dose:
- Has the patient been on the current dose for the minimum recommended period?
- Are appetite, glucose, weight or other treatment targets responding?
- Are nausea, vomiting, constipation, reflux or abdominal symptoms manageable?
- Is the patient able to eat and drink enough?
- Are there signs of dehydration, low blood glucose, malnutrition or another illness?
- Are other medicines contributing to symptoms or risk?
- Is the product authentic and being used as designed?
This is why an online comparison is unreliable. Two people may be using different products, for different indications, with different medical histories and different treatment goals.
Side effects are not a scorecard
Some people assume that strong nausea means strong weight loss. That is unsafe reasoning. Severe symptoms can lead to dehydration, kidney injury, inadequate nutrition or a missed diagnosis. They may also make treatment impossible to continue.
The aim is not to suppress eating at any cost. A medically sound plan should preserve hydration, nutrition and daily function while monitoring benefit. If side effects are persistent or significant, contact the prescriber rather than pushing through solely to reach the next dose.
For practical guidance on bowel symptoms, see Constipation on GLP-1 Treatment. For urgent warning signs, see GLP-1 Red Flags.
A plateau does not automatically mean “go higher”
Weight does not fall in a straight line. Fluid shifts, menstrual cycles, changes in movement, sleep, intake, constipation and normal measurement variation can all affect the scale. A genuine plateau may also occur as the body adapts to weight loss.
A sensible plateau review checks the trend over time, adherence, nutrition, activity, sleep, other medicines and the original treatment goals. The clinician can then decide whether the current dose remains appropriate, whether a labelled escalation is reasonable, or whether another problem needs attention.
Automatically increasing the dose can miss issues such as severe constipation, inadequate protein intake, loss of lean tissue, depression, binge eating, medicine interactions or poor product quality.
Avoid improvised dosing
Do not shorten the interval between injections, take an extra dose after a missed dose, share a pen, transfer medicine between devices, or calculate an unapproved number of “clicks” based on social-media instructions. Follow the instructions for the exact product and ask a pharmacist or prescriber when the device or missed-dose guidance is unclear.
Extra caution is needed with compounded or unapproved products. Regulators have reported dosing errors, including confusion between milligrams, millilitres and syringe units. SAHPRA and the FDA have also warned about unregistered, falsified and non-approved GLP-1 products. Use a legitimate supply chain and a clearly labelled product.
Define success more broadly
Success may include better glucose control, improved mobility, reduced waist circumference, more manageable hunger, improved health markers or clinically meaningful weight reduction. The plan should also consider muscle, nutrition, tolerability, cost and sustainability.
If appetite-related thoughts become louder again, that does not automatically mean personal failure or immediate dose escalation. Read What Is Food Noise - and Why Can It Return? for a more useful way to think about it.
Before Your Next Injection provides a fuller GLP-1 weight-loss guide to dose decisions, plateaus, side effects and long-term planning.
Medical disclaimer: This article is general education, not an individual dosing plan. Follow the approved instructions for your exact medicine and country. Do not change a prescription dose or schedule without the prescribing clinician.
Sources: FDA Wegovy prescribing information; FDA Zepbound prescribing information; FDA alert on dosing errors with compounded injectable semaglutide; SAHPRA GLP-1/GIP product warning.